Immunotherapy and chemotherapy before surgery for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that is stage III or IV.
- You are able to have surgery to remove the tumor (debulking surgery).
- You have not previously been treated with immunotherapy drugs (like checkpoint inhibitors).
- You have no uncontrolled heart or brain conditions.
- You have no other cancer in the past 3 years except for very early skin or cervical cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
This trial tests two oral medications, pamiparib and surufatinib, given before surgery to shrink advanced ovarian cancer. The goal is to make surgery more successful and potentially improve outcomes for patients who cannot have surgery right away.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.